JP2021529559A5 - - Google Patents
Info
- Publication number
- JP2021529559A5 JP2021529559A5 JP2021522932A JP2021522932A JP2021529559A5 JP 2021529559 A5 JP2021529559 A5 JP 2021529559A5 JP 2021522932 A JP2021522932 A JP 2021522932A JP 2021522932 A JP2021522932 A JP 2021522932A JP 2021529559 A5 JP2021529559 A5 JP 2021529559A5
- Authority
- JP
- Japan
- Prior art keywords
- immune cell
- nucleotide sequence
- immune
- cancer
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076738A JP2024102286A (ja) | 2018-07-03 | 2024-05-09 | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693677P | 2018-07-03 | 2018-07-03 | |
| US201862693668P | 2018-07-03 | 2018-07-03 | |
| US62/693,677 | 2018-07-03 | ||
| US62/693,668 | 2018-07-03 | ||
| US201862713369P | 2018-08-01 | 2018-08-01 | |
| US62/713,369 | 2018-08-01 | ||
| US201862756698P | 2018-11-07 | 2018-11-07 | |
| US201862756664P | 2018-11-07 | 2018-11-07 | |
| US62/756,664 | 2018-11-07 | ||
| US62/756,698 | 2018-11-07 | ||
| PCT/US2019/040346 WO2020010110A1 (en) | 2018-07-03 | 2019-07-02 | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076738A Division JP2024102286A (ja) | 2018-07-03 | 2024-05-09 | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529559A JP2021529559A (ja) | 2021-11-04 |
| JP2021529559A5 true JP2021529559A5 (enExample) | 2022-07-12 |
Family
ID=69060204
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522932A Pending JP2021529559A (ja) | 2018-07-03 | 2019-07-02 | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
| JP2024076738A Pending JP2024102286A (ja) | 2018-07-03 | 2024-05-09 | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076738A Pending JP2024102286A (ja) | 2018-07-03 | 2024-05-09 | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3817763B1 (enExample) |
| JP (2) | JP2021529559A (enExample) |
| KR (1) | KR20210030950A (enExample) |
| CN (1) | CN112638402A (enExample) |
| AU (1) | AU2019299439C1 (enExample) |
| CA (1) | CA3104862A1 (enExample) |
| IL (1) | IL279629A (enExample) |
| WO (1) | WO2020010110A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102907902B1 (ko) | 2018-08-01 | 2026-01-02 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 |
| WO2020037066A1 (en) | 2018-08-14 | 2020-02-20 | Unum Therapeutics Inc. | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| WO2021154218A1 (en) * | 2020-01-28 | 2021-08-05 | Nantkwest, Inc. | Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors |
| EP4178974A4 (en) * | 2020-07-09 | 2024-10-30 | The Board of Trustees of the Leland Stanford Junior University | IMMUNE CELLS WITH INCREASED GLYCOLYTIC FLOW |
| WO2022140361A1 (en) * | 2020-12-22 | 2022-06-30 | Ludwig Institute For Cancer Research Ltd | Genetically engineered lymphocytes for adoptive cell therapy |
| US20240108652A1 (en) * | 2021-02-18 | 2024-04-04 | University Of Florida Research Foundation, Incorporated | Enhancing metabolic fitness of t cells to treat cancer |
| US20240197881A1 (en) * | 2021-04-23 | 2024-06-20 | Sorrento Therapeutics, Inc. | Dimeric Antigen Receptors (DARs) that Bind GD2 |
| MX2024004009A (es) * | 2021-09-27 | 2024-06-19 | Sotio Biotech Inc | Polipéptidos receptores quiméricos en combinación con moléculas transmetabólicas que redirigen metabolitos de glucosa fuera de la vía de la glucólisis y usos terapéuticos de estos. |
| EP4429676A4 (en) * | 2021-11-08 | 2025-08-20 | Memorial Sloan Kettering Cancer Center | IMMUNE CELLS EXPRESSING GLUCOSE TRANSPORTER 5 (GLUT5) AND COMPOSITIONS AND METHODS COMPRISING SAME |
| CA3237201A1 (en) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| GB202118201D0 (en) | 2021-12-15 | 2022-01-26 | King S College London | Engineered immune cell |
| US20250382382A1 (en) * | 2022-03-08 | 2025-12-18 | Synthekine, Inc. | Orthogonal gpc3 chimeric antigen receptor t cells |
| CN115678856A (zh) * | 2022-06-09 | 2023-02-03 | 郑州大学第一附属医院 | 一种肿瘤杀伤细胞及其应用 |
| WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
| US20260053924A1 (en) | 2022-08-19 | 2026-02-26 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| AU2025207075A1 (en) * | 2024-01-09 | 2026-08-06 | Arc Therapies Inc. | Survivor t cells, survivor t cell population, and pharmaceutical composition |
| TW202540408A (zh) * | 2024-01-09 | 2025-10-16 | 國立研究開發法人國立癌症研究中心 | 需要時葡萄糖攝取能力經強化之ｔ細胞、細胞集團及含有此之醫藥組成物 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM. |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU7477394A (en) | 1993-07-30 | 1995-03-27 | University Of Medicine And Dentistry Of New Jersey | Efficient gene transfer into primary lymphocytes |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| US5756910A (en) | 1996-08-28 | 1998-05-26 | Burgett, Inc. | Method and apparatus for actuating solenoids in a player piano |
| EP0968284B1 (en) | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU2474700A (en) | 1998-12-01 | 2000-06-19 | Genentech Inc. | Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
| JP2002541845A (ja) | 1999-04-16 | 2002-12-10 | セルテック セラピューティックス リミテッド | 合成膜貫通成分 |
| AU2271801A (en) * | 1999-12-21 | 2001-07-03 | Zymogenetics Inc. | Human slit polypeptide zslit3 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| KR102308597B1 (ko) | 2013-10-17 | 2021-10-01 | 내셔널 유니버시티 오브 싱가포르 | 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체 |
| US10246505B2 (en) * | 2013-11-25 | 2019-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control HIV infection |
| WO2016040441A1 (en) | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
| US11020429B2 (en) * | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| EP3430036A4 (en) | 2016-03-18 | 2019-08-14 | Unum Therapeutics | MODIFIED CHIMERIC RECEPTORS AND USES IN IMMUNOTHERAPY |
| KR102614675B1 (ko) * | 2016-04-15 | 2023-12-19 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
| CN105949324B (zh) * | 2016-06-30 | 2019-08-27 | 上海恒润达生生物科技有限公司 | 靶向gpc3的嵌合抗原受体及其用途 |
| CN110121352B (zh) * | 2016-09-01 | 2020-12-11 | 嵌合体生物工程公司 | Gold优化的car t-细胞 |
| CN117298260A (zh) * | 2016-09-02 | 2023-12-29 | 莱蒂恩技术公司 | 用DuoCAR治疗癌症的组合物和方法 |
| JP7467117B2 (ja) * | 2016-10-07 | 2024-04-15 | ノバルティス アーゲー | 癌の治療のためのキメラ抗原受容体 |
| CN112888786A (zh) * | 2018-09-07 | 2021-06-01 | Sotio有限责任公司 | 与调节细胞内乳酸浓度的反式代谢分子组合的嵌合受体多肽及其治疗用途 |
-
2019
- 2019-07-02 WO PCT/US2019/040346 patent/WO2020010110A1/en not_active Ceased
- 2019-07-02 CN CN201980056724.9A patent/CN112638402A/zh active Pending
- 2019-07-02 KR KR1020217003418A patent/KR20210030950A/ko not_active Ceased
- 2019-07-02 CA CA3104862A patent/CA3104862A1/en active Pending
- 2019-07-02 AU AU2019299439A patent/AU2019299439C1/en active Active
- 2019-07-02 JP JP2021522932A patent/JP2021529559A/ja active Pending
- 2019-07-02 EP EP19831325.6A patent/EP3817763B1/en active Active
-
2020
- 2020-12-21 IL IL279629A patent/IL279629A/en unknown
-
2024
- 2024-05-09 JP JP2024076738A patent/JP2024102286A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021536265A5 (enExample) | ||
| JP2021534740A5 (enExample) | ||
| US12410248B2 (en) | Chimeric antigen receptor and its use | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| JP7175769B2 (ja) | 改善された養子ｔ細胞療法 | |
| US12076378B2 (en) | Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors | |
| Guest et al. | The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens | |
| CN105153315B (zh) | 免疫抑制受体联合肿瘤抗原嵌合受体及其应用 | |
| JP2022512958A5 (enExample) | ||
| CN109053899B (zh) | 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体 | |
| JP2024023228A5 (enExample) | ||
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| EP2709671A1 (en) | Method | |
| WO2017112877A1 (en) | Chimeric antigen receptors and enhancement of anti-tumor activity | |
| Pameijer et al. | Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor | |
| CN109280086B (zh) | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 | |
| CN109789164B (zh) | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 | |
| JP2024536859A5 (enExample) | ||
| US20220298223A1 (en) | B CELL TARGETED PARALLEL CAR (pCAR) THERAPEUTIC AGENTS | |
| EP3098237A1 (en) | Anti-toso chimeric antigen receptor and its use | |
| KR20230061486A (ko) | 면역 세포 내 어댑터의 유도성 발현을 위한 시스템 | |
| WO2019115818A2 (en) | Pooling signaling and costimulatory domains in flexible car design | |
| Vyas et al. | Mono-and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia | |
| JP2022551455A (ja) | 操作された免疫細胞 | |
| EP4719465A1 (en) | Synthetic cancer antigens as targets for treating cancers |